Major Upcoming Milestones (The Manila Times) - Aug 6, 2026 - "Immunovant expects to report topline data from the proof-of-concept trial of IMVT-1402 in CLE and provide an update on the potentially registrational program of IMVT-1402 in D2T RA in the second half of calendar year 2026. In calendar year 2027, topline data are expected across potentially registrational trials of IMVT-1402 in GD and MG. In calendar year 2028, topline data are expected across potentially registrational trials of IMVT-1402 in CIDP and SjD."
P2 data • P3 data: top line • Cutaneous Lupus Erythematosus • Grave's Disease • Immunology • Myasthenia Gravis • Rheumatoid Arthritis • Sjogren's Syndrome
|